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’INTRODUCTION
With rapid and ongoing developments in sample preparation,
instrumentationand computational analysis, mass spectrometry-
based quantitative proteomics is increasingly emerging as an
approach of choice for addressing many aspects of biology.
13
One of the most popular formats of relative quantitative pro-
teomics,
4 stable-isotope labeling by amino acids in cell culture
(SILAC),
5 relies on internal metabolic labeling of cellular pro-
teomes under study. Conversely, absolute protein quantitation
with stable isotopes depends on the external generation of
isotopically labeled standards to accurately determine protein
abundance in biological samples. This approach has been used
for some time and has promising applications in systems biology
and biomarker discovery. However, the popular employment of
isotope-labeled peptides as standards, either synthesized chem-
ically
6orexpressedintheformofaconcatamer,
7faceslimitations
compared to the more recently developed quantitation with full-
length labeled proteins.
8 The important advantage of the latter
approach, termed absolute SILAC
9 or PSAQ (protein standard
absolute quantiﬁcation),
8 is that standards are introduced earlier
in the workﬂow and are subjected to the same fractionation and
digestion conditions as the endogenous counterpart, thereby
providing more reliable quantitation. Until now, a limited
number of labeled standards have been produced for speciﬁc
mass spectrometric measurements, resulting in a single proof-
of-principle study with little further use of the material.
715 For
single studies, picomole quantities of standard are often suﬃ-
cient; however, systems biology and biomarker discovery appli-
cations will require large-scale production of stringently quality
controlled standards. Large-scale labeled protein production
fulﬁlls the current trend toward uncoupling the production of
standards from the actual experiment by centrally producing
labeled proteins and distributin g them for use by the scientiﬁc
community. A notable example of this trend is the super SILAC
approach,
16 in which libraries of labeled cell lines are centrally
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standards. To optimize production of isotopically labeled stan-
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expression Escherichia coli strain, BL21 (DE3), to construct an
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low-cost, high-level expression of fully labeled proteins with no
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ﬂuorescence-based quantitation of standards and nontargeted
LCMS/MS analysis of unfractionated total cell lysates, this strain was used to determine the copy number of a post-translational
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preparedanddistributedtoend-userlaboratories.Inthiscontext,
the widespread uptake of absolute SILAC depends strongly on
how inexpensively and eﬃciently labeled proteins can be
produced.
To address this need, we have generated a lysine and arginine
auxotrophic form of the popular protein expression strain E. coli
BL21 (DE3). The strain can be used in conjunction with com-
monly applied prokaryotic protein expression techniques to
express relatively large quantities of proteins labeled 100% with
“heavy”lysineandarginineresidues,withnoappreciablearginine
to proline conversion. We demonstrate the application of the
technology by expressing a
13C6
15N4-arginine and
13C6
15N2-
lysinelabeledformoftheSmallubiquitin-likemodiﬁer(SUMO-2)
17
anduseittocalculatethecopynumberofSUMO-2inHeLacells
and two clinical samples.
’MATERIALS AND METHODS
Generation of an E. coli BL21 (DE3) Strain Auxotrophic for
Arginine and Lysine
Auxotrophic mutants of E. coli BL21 (DE3)
18 were con-
structed by bacteriophage P1 transduction
19 to introduce in-
frame deletions in lysA and argA genes from the Keio Collection
of single-gene knockout library.
20 The deleted genes were re-
placed by a kanamycin resistance gene ﬂanked by two FLP
recombinase target sites, and the P1 lysates were prepared from
lysA and argA mutants retrieved from the Keio Collection. P1
transduction was then carried out according to standard proce-
dures as described previously
19 to introduce each mutation into
the recipient E. coli BL21 (DE3). Following the selection of the
transductants in the presence of kanamycin, the kanamycin resis-
tance cassette was removed by the transient expression of FLP
recombinaseaccordingtotheprocedureofDatsenkoandWanner.
21
This was repeated to obtain a strain with dual auxotrophy.
Expression, Purification and Quantitation of the Labeled
Standard
The mature form of human SUMO-2 was subcloned into a
pHisTEV vector and expressed in Escherichia coli BL21 (DE3)
ΔlysA ΔargA cells as an N-terminally His-tagged protein. Ex-
pression was performed in M9 medium supplemented with
0.2% glucose, 50 μg/mL kanamycin, 1 mM MgSO4,5 0μg/mL
13C6
15N4-arginine and 50 μg/mL
13C6
15N2-lysine (Cambridge
Isotope Laboratories, Andover, MA). After harvesting, recombi-
nant,isotopicallylabeledSUMO-2waspuriﬁedbyNi-NTA(Ni
2+-
nitrilotriacetate)-aﬃnity chromatography. After this ﬁrst puriﬁ-
cation step, the His-tag was removed by Tobacco Etch Virus
(TEV) Protease in 50 mM Tris/HCl pH 8.0, 5 mM β-mercap-
toethanol and 50 mM NaCl and puriﬁed further by Ni-NTA-
aﬃnity chromatography and on a gel ﬁltration Superdex-75
column (GE Healthcare, Piscataway, NJ).
6His-TEV-YFP-SUMO-2-FL-ECFP was expressed in E. coli
B834 (DE3) and puriﬁed from bacterial lysates using Ni-NTA-
aﬃnity chromatography and anion-exchange chromatography as
described.
22Concentrationof6His-TEV-YFP-SUMO-2-FL-ECFP
was calculated by measuring absorbance of ECFP at 433 nm and
of YFP Venus
23 at 515 nm. The average of 20 measurements of
absorbances was used and determined the concentration based
on the Beer’s law and extinction coeﬃcients for YFP and ECFP
(92,200 and 28,750 M
1 cm
1, respectively).
22 Isotopically
labeled SUMO-2 standard and 6His-TEV-YFP-SUMO-2-FL-
ECFP were mixed, digested with the FASP method, as des-
cribed below, and analyzed by mass spectrometry. The exact
concentration of the labeled SUMO-2 standard was calculated
from SILAC ratios based on the ﬂuorescently determined
concentration of 6His-TEV-YFP-SUMO-2-FL-ECFP.
Cell Preparation and Counting
Sperm Cells. Semen was collected from healthy normozoos-
permic (as defined by WHO (1999) guidelines) donors. Re-
search donors were recruited at Ninewells Hospital, Dundee
(HFEACentre 004) in accordancewiththe Human Fertilisation
and Embryology Authority Code of Practice Version 8 under
local ethical approval (08/S1402/6) from Tayside Committee
on Medical Research Ethics. Sperm cells were isolated using a
2 layer density gradient composed of 40% and 80% PureSperm-
(NidaconIntAB,M€ olndal,Sweden)bufferedwithnoncapacitat-
ing buffer (NCB) [1.8 mM CaCl2, 5.4 mM KCl, 0.8 mM
MgSO4.7H2O, 116.4 mM NaCl, 1.0 mM NaH2PO4, 5.6 mM
D-glucose, 2.7 mM Na pyruvate, 41.8 mM Na lactate, 25 mM
HEPES,pH7.4].Semen(maximumof1mL)waslayeredontop
of each gradient and centrifuged at 300 g for 20 min in 15 mL
conical centrifuge tubes. The 80% fractions were transferred to
clean tubes by discarding the seminal fluid and the bulk of the
densitygradientthenretrievingthespermpelletfromthebottom
of the tube taking care to avoid contamination. Sperm cells were
washedinNCBthencentrifugedat500gfor5min.Theresulting
pellets were resuspended in NCB. White blood cells were
removed using CD45 Dynabeads (Invitrogen, Paisley, Scotland) in
accordance to the manufacturer’s instructions. Ten fractions of each
cell suspension were mixed with water (to dilute and immobilize)
andcellswerecountedusinganimprovedNeubauerhemocytometer
(Weber Scientific International Ltd., Middlesex, U.K.).
Chronic Lymphocytic Leukemia (CLL) Cells. Studies in-
volving isolation and analysis of human chronic lymphocytic
leukemia cells (CLL) were approved by the Tayside Committee
on Medical Research Ethics and Tayside Tissue Bank. Following
informed consent, an enriched population of CLL cells was
obtained by density gradient centrifugation (Ficoll-PaqueTM
Plus, 1.077, GE Healthcare Bio-Sciences AS, Uppsala) from
20 mL of blood. Cells were counted with a Coulter counter
(Beckman Coulter, Hialeah, FL).
HeLa Cells. HeLa cells were cultured in DMEM medium
supplemented with 10% FBSand 100units/mlpenicillin and strep-
tomycin. Cells were counted using the Cellometer Auto T4 Auto-
matic cell counter (Nexcelom Bioscience LLC, Lawrence, MS).
Cell Lysis and Protein Digestion
Cellpelletswerelysedin100mMTris-HCl(pH7.5)contain-
ing 4% SDS and processed by the FASP method.
24 The lysates
were sonicated to reduce viscosity and incubated at 95 C for
5 min. Following centrifugation for 20 min at 21000 g, the
supernatant was mixed with UA buﬀer (200 μL of 8 M urea in
100 mM Tris-HCl, pH 7.5), loaded onto Vivacon 500 μL
ultraﬁltration spin columns with nominal cutoﬀ of 30000 Da
(Sartorius Stedim Biotech, Epsom, U.K.) and centrifuged at
14000 g for 15 min. The samples were washed with 200 μLo f
UA buﬀer and centrifuged again to remove SDS. The concen-
trates were diluted with 100 μLo fU Ab u ﬀer containing 50 mM
iodoacetamide and incubated in darkness for 30 min. After cen-
trifugation the samples were washed three times with 200 μLo f
UA buﬀer and twice with 100 μL of 50 mM NaHCO3. Next,
50 μL of 50 mM NaHCO3 containing 2 μg of trypsin (Promega,
Madison, WI) was added to the concentrate and the samples
were incubated at room temperature overnight. The resulting
digested peptides were eluted by centrifugation followed by two4871 dx.doi.org/10.1021/pr2004715 |J. Proteome Res. 2011, 10, 4869–4875
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additional elutions with 50 μL of 50 mM NaHCO3 and were
evaporatedtodrynessinavacuumconcentratorsystem(Concen-
trator Plus, Eppendorf, Hamburg, Germany) to remove NaH-
CO3. The dried residues were reconstituted in 40 μLo fb u ﬀer A
(0.5% acetic acid) and transferred to vials for MS analysis.
Liquid ChromatographyMass Spectrometry and Data
Analysis
Mass spectrometric analysis was performed by nanoscale
LCMS/MSusinganLTQ-OrbitrapVelosinstrument(Thermo
Fisher Scientiﬁc, Bremen, Germany) coupled to an Ultimate
U3000 (Dionex Corporation, Sunnyvale, CA) via a Proxeon
nanoelectrospray source (Proxeon Biosystems, Denmark). Pep-
tides were separated on a 75 μm PepMap C18 nano column
(Dionex).
Data were acquired in data-dependent mode: full scan spectra
were acquired with a resolution of 60000 after accumulation of
1000000 ions. The “lock mass” option was used to improve the
massaccuracyofprecursorions.
25The10mostintenseionswere
fragmented by collision-induced dissociation (CID) with nor-
malized collision energy of 35% and recorded in the linear ion
trap (target value of 5000) based on the survey scan and in
parallel to the orbitrap detection of MS spectra.
Raw MS data were processed with MaxQuant, an integrated
suiteofsoftwareforquantitativeproteomics(version1.1.1.25).
26,27
Enzyme speciﬁcity was set to trypsin, allowing for cleavage N-
terminal to proline residues and up to two missed cleavages.
Cysteine carbamidomethylation was considered as a ﬁxed mod-
iﬁcation, and methionine oxidation and protein N-acetylation
were set as variable modiﬁcations. MS/MS peak lists generated
by MaxQuant were searched by the Andromeda database search
engine
27 against the human International Protein Index (IPI)
database (version 3.68).
28
’RESULTS AND DISCUSSION
Generation of an Absolute SILAC-Compatible Bacterial Pro-
tein Expression Strain
Widespread use of absolute SILAC and its application in
biomarker discovery and systems biology, which is the ultimate
goal of absolute quantitation, rely on eﬃcient and inexpensive
production of protein standards. “Heavy” arginine and lysine are
the most frequently used stable isotope-labeled amino acids in
SILAC-based studies; however, these amino acids are nonessen-
tial to commonly available E. coli expression strains. Hence, the
endogenous production of lysine and arginine in a regular
expression strain dramatically compromises the incorporation
eﬃciency.
10 Conversely, the use of strains auxotrophic for lysine
and arginine, but not optimized for protein expression, leads to
nonoptimal expression.
9 Cell-free synthesis, an alternative ap-
proachthatinabsenceofadedicatedabsoluteSILAC-compatible
strainhasinsomecasesbeenusedtoproducelimitedamountsof
a standard,
8,9,11 suﬀers from higher costs, relatively low levels of
protein expression, diﬃculties in protein puriﬁcation and occa-
sionally incomplete labeling.
11
To obtain both the full incorporation of SILAC amino acids
and optimal protein yields, the E. coli BL21 (DE3) strain
18 was
modiﬁed to be auxotrophic for lysine and arginine. BL21 (DE3)
isawidelyusedE.colistrainforhigh-levelproteinexpressionthat
employs the T7 RNA Polymerase-based system, carries addi-
tional tRNAs to overcome the problem of codon bias and is
protease compromised to minimize post-translational proces-
sing. To abolish the synthesis of lysine and arginine we deleted
the diaminopimelate decarboxylase (lysA) and N-acetylgluta-
mate synthase (argA) genes by using the Keio collection of
mutants,
20 which allows in-frame single-gene deletion of target
genes (Figure 1A and Materials and Methods). An advantage of
the system is that the same cosmid and resistance marker can be
employed to make multiple knockouts due to the elimination of
the resistance marker by FLP recombinase. Therefore, this
auxotrophic strain does not have any antibiotic resistance and
is amenable to generation of any protein that can be expressed
recombinantly.Arginineandlysineauxotrophywasconﬁrmedby
the absence of growth in the minimal medium without added
arginine or lysine (Figure 1B). Importantly, although in many
cases proteins expressed in E. coli are insoluble, whether or not
the protein of interest is soluble is inconsequential for this
methodasinsolubleaggregatesareeasilyandcompletelypuriﬁed
by diﬀerential centrifugation and on metal aﬃnity resins in pre-
sence of urea. The recently developed FASP digestion
24 allows
complete solubilization of proteins under highly denaturing
conditions before buﬀer exchange on the ﬁlter and subsequent
proteolytic digestion. Our strategy for the production of labeled
standards and their incorporation into the workﬂow of quanti-
tative mass spectrometry are outlined in Figure 2A.
Expression of
13C6
15N4-Arginine and
13C6
15N2-Lysine La-
beled SUMO-2
After optimization of growth conditions (see Materials and
Methods), we expressed and puriﬁed 30 mg of labeled SUMO-2
from0.5Lofmodiﬁedmedium.Consideringmaterialsalone,this
equates to less than 4 US$ per mg protein by current materials
costs. His6-tagged SUMO-2 was puriﬁed by nickel aﬃnity
chromatography. The His6-tag was cleaved away from SUMO-
2 by TEV protease and untagged SUMO-2 was further puriﬁed
Figure 1. Bacterial strain for the production of SILAC-labeled SUMO-2. (A) Genetic modiﬁcation of the E. coli BL21 (DE3) strain. (B) SILAC-
compatible strain auxotroph for lysine and arginine. Growth on M9 minimal agar plates with and without lysine and arginine is shown.4872 dx.doi.org/10.1021/pr2004715 |J. Proteome Res. 2011, 10, 4869–4875
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by nickel aﬃnity chromatography and gel ﬁltration (Figure 2B).
Crucially, we achieved complete incorporation of isotopically
labeled arginine and lysine and observed no arginine to proline
conversion (Figure 3). This greater than 99.9% incorporation
level of isotope-labeled proteins compares favorably with those
generated in a regular BL21(DE3) strain (i.e., not auxotrophic
for arginine and lysine), which was only approximately 70%.
10
Incomplete labeling of the standard, especially in case of labeling
eﬃciency below 95%, constitutes a serious problem in the
quantitation of low abundance proteins that will be masked by
the contaminating “light” peptides. Similarly, metabolic conver-
sion of heavy arginine to heavy proline, reported in certain
microrganisms
29,30 and cell lines
31 but not here (Figure 3D),
compromises quantitation accuracy by creating multiple peaks
for every heavy proline-containing peptide.
Quantitation of the SUMO-2 Standard
The accuracy of quantitation of a protein of interest relies
on the knowledge of the concentration of the corresponding
standard.The commonly usedmethodsforprotein quantitation,
such as amino acids analysis and measurement of absorbance at
280 nm,
9 require the standard to be highly puriﬁed. Otherwise,
the presence of contaminating proteins would lead to an over-
estimation of the concentration of the standard. However, it is
oftendesirabletoavoidanextensivepuriﬁcationthatislaborious,
involves multiples steps and leads to loss of material. Here we
reasoned that ﬂuorescence spectroscopy combined with quanti-
tative mass spectrometry
11 can be used to determine the con-
centration of an absolute SILAC standard even in complex mix-
tures. Contaminating proteins do not absorb light at absorbance
wavelengths of ﬂuorescent proteins and are therefore invisibleto
ﬂuorescence measurements. Thus, we adapted a previously
developed ﬂuorescence-based strategy
11 to quantify the protein
concentration of the labeled SUMO-2 standard. First, we puriﬁed a
recombinant unlabeled YFP-ECFP fusion of SUMO-2
22 and calcu-
lated its concentration from the absorbance measurements of YFP
and ECFP. In the second step, the labeled SUMO-2 standard was
mixed with YFP-SUMO-2-ECFP, digested with trypsin and quanti-
ﬁed by mass spectrometry (Figure 2A; Materials and Methods).
The SILAC ratio between the isotope labeled, nonﬂuorescent
SUMO-2 and its ﬂuorescent analogue allows the calculation of
the concentration of the absolute SILAC SUMO-2 standard.
Itistheoreticallypossiblethattheaccuracyoftheﬂuorescence
strategyiscompromisedbytheincorrectfoldingofﬂuorophores.
Although the use of two ﬂuorophores might help to compensate
in case the activity of only one ﬂuorescent protein is compro-
mised, the incorrect folding of the whole fusion protein could
aﬀect both ﬂuorophores. However, YFP-SUMO2-ECFP is com-
pletely cleaved by the SUMO-2 protease,
22 and as protease cle-
avage is dependent on the folded structure of SUMO, it is likely
that the protein is correctly folded and that therefore the two
ﬂuorophores are active.
Absolute Quantitation of SUMO-2 in Clinical Samples
Because of its important role in both physiological and
pathologicalstates,suchascancer,
32and itsnatureasaprotein
modiﬁer, we reasoned that absolute SILAC would be the ideal
technique for the investigation of SUMO-2 as a biomarker.
SeveralstudieshavealreadysuccessfullyadaptedSILAC-based
proteomics to the investigation of sumoylation dynamics.
33,34
Hereweextendthescopeofquantitativeproteomicanalysisof
sumoylationtoincludeabsoluteSILAC.Asaproofofprinciple,
we decided to determine the absolute abundance of SUMO-2
in two clinically relevant human samples, namely sperm and
CLL cells, for which no evidence of SUMO-2 modiﬁcation has
been reported so far. Notably, this was achieved with no
fractionation of the sample and without any targeted proteo-
mics approach. CLL cells were isolated from peripheral blood
of a patient with chronic lymphocytic leukemia,
35 which is the
most common type of adult leukemia and involves uncon-
trolled proliferation of B-cells, whereas sperm cells
36 were
collected from healthy donors. Cell lysis was performed under
highly denaturing conditions to inactivate proteases and en-
sure complete solubilization of proteins. One of the main
advantages of absolute SILAC compared to peptide-based
absolute quantitation methods is that the standard can be
Figure 2. Experimental workﬂow. (A) Labeled SUMO-2 is recombi-
nantly expressed in the E. coli BL21 (DE3) strain auxotroph for
arginine and lysine and puriﬁed by nickel-aﬃnity column chromatog-
raphy and gel ﬁltration. Concentration of heavy SUMO-2 was cal-
culated by mass spectrometry using a ﬂuorescently labeled SUMO-2
as a reference. Isotopically labeled SUMO-2 was then spiked in cell
extracts to determine the copy number of endogenous SUMO-2. (B)
Puriﬁcation of the SUMO-2 standard labeled with heavy lysine and
arginine: lane M, molecular mass marker; lane 1, total cell lysate from
uninduced cells; lane 2, total bacterial extract from induced cells; lane 3,
supernatant; lane 4, pellet; lane 5, ﬂow-through from the Ni-NTA
column; lane 6, wash; lane 7, 6His-TEV-SUMO-2 puriﬁed from
Ni-NTA-aﬃnity column; lane 8, cleavage by TEV protease; lane 9,
puriﬁed SUMO-2.4873 dx.doi.org/10.1021/pr2004715 |J. Proteome Res. 2011, 10, 4869–4875
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added immediatelyafterlysisandbeforeany furthermanipula-
tion of the sample, thus minimizing variations in sample
preparation between endogenous protein and the standard.
AknownamountoftheheavySUMOstandardwasspikedinto
Figure 3. Complete incorporation of heavy isotopes and absence of arginine-to-proline conversion. Recombinant isotopically labeled SUMO-2
produced in BL21 (DE3) ΔlysA ΔargA was digested in solution with trypsin and analyzed by LCMS/MS. (A) Amino acid sequence of the SUMO-2
standard. Highlighted text indicates the peptides whose MS spectra are reported in the lower panels. The arrows show the isotopic distribution of the
heavypeptides andthecalculated positions ofthe lightcounterparts(BandC)or oftheheavy proline-containingpeptide(D). Incorporationeﬃciency
for both lysine (B) and arginine (C) containing peptides is greater than 99.9%. (D) Labeled arginine is not converted to heavy proline in BL21 (DE3)
ΔlysA ΔargA.4874 dx.doi.org/10.1021/pr2004715 |J. Proteome Res. 2011, 10, 4869–4875
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the sample and tryptic digestion was performed on a centrifugal
ﬁlter unit with nominal cutoﬀ of 30 kDa according to the FASP
protocol.
24 Note that the 30 kDa cutoﬀ was determined by the
manufacturer with folded rather than denatured proteins
24 and
that this ﬁlter eﬃciently retains detergent-denatured SUMO-2
(data not shown). Following digestion, peptides were eluted and
subjectedtoLCMS/MSanalysisandtheratiosweredetermined
by the MaxQuant data processing software
26 from 4 technical
replicates. CLL (chronic lymphocytic leukemia) cells had a copy
numbercomparabletoHeLacells(3.63(0.00310
6and3.80(
0.05  10
6 molecules per cell, respectively) whereas sperm cells
contained signiﬁcantly fewer copies of SUMO-2 (1.11 ( 0.05 
10
5 molecules per cell; Figure 4, Table 1).
PhysiochemicalpropertiesofSUMOconjugatedproteinsare
diﬀerent among themselves and as compared to unconjugated
SUMO and the labeled SUMO internal standard. Thus, no
fractionation should be performed at the protein level, as this
would compromise the accuracy of quantitation, but rather
proteins should be digested with an approach that does not
discriminatebetweendiﬀerentsubsetsofSUMO.Herewehave
employed the FASP approach, which allows complete solubi-
lization of proteins under highly denaturing conditions before
subsequentproteolyticdigestion.Afterdigestion,peptideswith
the same sequence derived from the heavy SUMO-2 standard
have, apart from the higher mass, the same physiochemical
properties of those derived from endogenous free and con-
jugated SUMO-2. Although in general a fractionation step at
the peptide level would not aﬀect the quantitation, it was not
necessary in this study as SUMO-2was detectableand quantiﬁ-
able in unfractionated complex mixtures.
’CONCLUSIONS
The bacterial strain described here allows high-yield and
inexpensive production of full-length SILAC labeled protein
standards with complete incorporation of labeled amino acids
and no proline to arginine conversion. BL21 (DE3) ΔlysA
ΔargA could either be employed directly by individual labora-
toriesoronelargebatchofrigorouslyqualitycontrolledprotein
standards could be produced centrally and distributed to ﬁnal
users.Lowcostproductionoflargeamountsoflabeledproteins
will also make feasible the production of more sophisticated
second-generation SILAC standards, such as the creation of
diﬀerent types of ubiquitin and SUMO polymers and phos-
phorylated proteins by postproduction in vitro reactions. In
addition, this system is not limited to the production of
proteins, but it can also generate multiple labeled peptides as
partofartiﬁcialproteins(QconCATs).
7,15Weenvisagethatour
strain will be widely used and that it will dramatically improve
the generation of labeled standards for absolute quantitation
using mass spectrometry.
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Figure 4. Copy number of SUMO-2. MS spectra of the doubly charged peptide VAGQDGSVVQFK from (A) HeLa, (B) sperm and (C) CLL cells.
Table 1. Copy Number of SUMO-2 for HeLa, Sperm and
CLL (Chronic Lymphocytic Leukemia) Cells
sample
number
of cells
ratio H/L
(mean ( SD
a)
pmol
endogenous
SUMO-2
moleculespercell
(mean ( SD
a)
HeLa cells 5.0010
5 8.44(0.10 1.90 3.80(0.05 10
6
Sperm cells 3.9510
6 36.42(1.67 0.44 1.11(0.05 10
5
CLL cells 3.00 10
6 2.95(0.03 10.89 3.63(0.003 10
6
aStandard deviation (SD) is calculated from technical replicates.4875 dx.doi.org/10.1021/pr2004715 |J. Proteome Res. 2011, 10, 4869–4875
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